For Sophie Kornowski, a biotech specialist, artificial intelligence has analytical capabilities that allow precise targeting of treatments to patients
A medicine is 2.3 billion francs of investment. From the creation of the molecule, through all the stages of the regulation, until its commercialization. “Biotech companies produce half of the innovative molecules that arrive every year on the market,” says Sophie Kornowski, of Gurnet Point Capital, an investment fund specializing in health, founded by Ernesto Bertarelli (formerly Serono) and directed by Christopher Viehbacher (formerly Sanofi).
